LONDON – If the claim is true, then drug delivery has never been so exciting, or more profound. "We are rethinking psychiatry," said Richard Pops, CEO of Alkermes plc, giving an update on the portfolio at the company's R&D day.
An emergency committee convened by World Health Organization (WHO) director-general, Margaret Chan, concluded that at this point, the Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV) does not warrant being declared a public health emergency of international concern.
• Mesoblast Ltd., of Melbourne, Australia, received about $4.3 million under the Australian government's Innovation Australia Research and Development Tax Incentive Program. The funds will be used to advance development of Mesoblast's mesenchymal precursor cell technology platform and product pipeline.
SHANGHAI – Glaxosmithkline plc sent three top global executives to China to deal with an expanding scandal that has seen four executives detained and one confess on national television.
SHANGHAI – Officials in China said a number of executives at Glaxosmithkline plc (GSK) are now officially under investigation "for suspicions of serious economic crimes" that potentially involve deals worth ¥3 billion (US$488 million).
LONDON – A faulty gene that plays a role in heart development is responsible for many cases of heart failure, an international team of researchers has shown.
LONDON – The European Union said the second phase of the Innovative Medicines Initiative (IMI 2) will get under way in January 2014 with a budget of €3.45 billion (US$4.5 billion) to be devoted to the development of vaccines and treatments for a range of chronic and degenerative diseases.
Ariana Pharma SA is developing software to guide the selection of personalized cancer care as part of a clinical trial in patients which, the study investigators claim, will be the first to offer all participants a treatment regimen based on their individual DNA, RNA and microRNA profiles.
LONDON – The UK botulinum toxin specialist Syntaxin Ltd. is to be acquired by research partner and equity investor Ipsen SA in a deal that potentially is worth €158 million (US$205.8 million), with €28 million to be paid up front, and the remainder tied to development and commercialization milestones.
RSS